Jobs
-
Dance Biopharm announced that it has bought back the Asia license for its Dance-501 soft mist inhaled insulin by purchasing the license holder, Harmony Biopharm Limited, from Harmony Plus Holdings Limited (Harmony). Dance said that… Read more . . .
-
RDD Online has announced that nominations are open for the 2018 Charles G. Thiel Award, and the committee will accept nominations through November 30, 2017. The award will be presented at RDD 2018, which will… Read more . . .
-
Acorda Therapeutics has received a refusal to file letter from the FDA in response to its NDA for Inbrija (CVT-301) inhaled levodopa for the treatment of OFF periods in Parkinson’s disease patients, the company said.… Read more . . .
-
Chinese inhaled drug developer and CDMO CF PharmTech has raised $65M in a Series D financing round led by Future Industry Investment Fund (managed by SDIC Fund Management), the company said. The money is to… Read more . . .
-
Propeller Health and GSK have announced that their December 2015 agreement for development of a sensor for use with the Ellipta dry powder inhaler has been expanded, and R&D activities related to the use of… Read more . . .
-
A US company is selling a device marketed under the name Loli-O that promises delivery of nebulized medication to a child in the form of a cloud that emerges around a lollipop while the child… Read more . . .
-
Altimmune has submitted an investigational new drug application to FDA for its NasoVAX intranasal flu vaccine and is planning a Phase 2 study of the product, the company said. The safety and immunogenicity study is… Read more . . .
-
Hong Kong-based Lee’s Pharmaceutical will advance Windtree Therapeutics up to $3.9 million through the end of October 2017 during negotiations for Lee’s to acquire a controlling interest in Windtree. The first installment of the loan… Read more . . .
-
Adherium has now manufactured and sold 100,000 of its Smartinhaler inhaler monitoring devices, the company has announced. According to Adherium, the Smartinhaler has been sold in more than 40 countries to date. The Smartinhaler platform… Read more . . .
-
Hemispherx Biopharma has announced that a safety study of Ampligen plus FluMist in 25 healthy volunteers showed that intranasal Ampligen was generally well tolerated. Ampligen is a TLR-3 agonist, which the company is already developing… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA